Your search history is turned on.
Date: November 15, 2023 Jurisdictions: Quebec
NYMOX PHARMACEUTICAL CORP FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant ...
NYMOX PHARMACEUTICAL CORP EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a...
Date: August 14, 2023 Jurisdictions: Quebec
NYMOX PHARMACEUTICAL CORP EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate...
NYMOX PHARMACEUTICAL CORP FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant fil...
Date: November 16, 2022 Jurisdictions: Quebec
EXHIBIT99.3 CERTIFICATION I,RandallJ,Lanham,COOofNymoxPharmaceuticalCorporation,certifythat: 1. IhavereviewedthisquarterlyreportfortheperiodendedSeptember30,2022ofNymoxPharmaceuticalCorporation 2. Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterialfactnecessarytomakethe ...
EXHIBIT99.2 CERTIFICATION I,PaulAverback,PresidentandCEOofNymoxPharmaceuticalCorporation,certifythat: 1. IhavereviewedthisquarterlyreportfortheperiodendedSeptember30,2022ofNymoxPharmaceuticalCorporation 2. Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterialfactnecessarytomake...
NYMOX PHARMACEUTICAL CORP FORM6K SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 ReportofForeignIssuer PursuanttoRule13a16or15d16 undertheSecuritiesExchangeActof1934 FortheperiodendedSeptember30,2022 CommissionFileNumber:00112033 NymoxPharmaceuticalCorporation Indicatebycheckmarkwhethertheregistrantfilesorwill...